Cancer immunotherapy has been proven to be clinically effective in multiple types of
cancers.
Lymphocyte function-associated antigen 1 (LFA-1), a member of the
integrin family of adhesion molecules, is expressed mainly on αβ T cells.
LFA-1 is associated with
tumor immune responses, but its exact mechanism remains unknown. Here, two kinds of mice
tumor model of
LFA-1 knockout (LFA-1-/-) mice bearing subcutaneous
tumor and Apc Min/+;LFA-1-/- mice were used to confirm that
LFA-1 knockout resulted in inhibition of
tumor growth. Furthermore, it also demonstrated that the numbers of regulatory T cells (Treg cells) in the spleen, blood, mesenteric lymph nodes were decreased in LFA-1-/- mice, and the numbers of Treg cells in mesenteric lymph nodes were also decreased in Apc Min/+;LFA-1-/- mice compared with Apc Min/+ mice.
LFA-1 inhibitor (BIRT377) was administered to subcutaneous
tumor-bearing LFA-1+/+ mice, and the results showed that the
tumor growth was inhibited and the number of Treg cells was reduced. The analysis of TIMER
tumor database indicated that
LFA-1 expression is positively associated with Treg cells and TNM stage. Conclusively, this suggests that
LFA-1 knockout would inhibit
tumor growth and is correlated with Treg cells.
LFA-1 may be one potential target for
cancer immunotherapy. Video Abstract.